Uncategorized

Hospitals in 16 states have sued the department, arguing a 2023 final rule underpays hospitals that treat a disproportionate number of low-income patients.

Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat heart attack patients who don’t have cardiogenic shock.

Senators praised a recent CMS proposal aimed at reducing payments in MA, but urged the agency to work with Congress and go further.

Of the 11 companies participating in the spring cohorts of the Drive program run by MassBio and SCbio, eight have locations in Massachusetts. One cohort focuses on biotech and the other on biomarkers and diagnostics.

La revolución digital ha impactado prácticamente todos los sectores, pero el universo de las apuestas online se encuentra a la vanguardia gracias a la irrupción de la tecnología blockchain. En poco tiempo, conceptos que antes resultaban ajenos para muchos, como la descent …

The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma. The biotech has now gone under.

The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. The pharma refused.

While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.

Biogen, Eli Lilly, Merck and Novartis spent more than $20 billion to absorb biotechs with promising or approved drugs; the rare disease space notched approvals for therapies from Denali Therapeutics, Rocket Pharmaceuticals and Biogen; and Wave’s stock lost half its value after its RNA-based obesity candidate failed to impress investors.

Thousands of employees of the Department of Health and Human Services were fired last spring. Their colleagues are still picking up the pieces.